Explore

ITOCHU Strengthens Drug Development Support with AI-Driven Technologies Through MOLCURE Alliance

ITOCHU Strengthens Drug Development Support with AI-Driven Technologies Through MOLCURE Alliance

ITOCHU Strengthens Drug Development Support with AI-Driven Technologies Through MOLCURE Alliance

Rockwell Automation and Industry Leaders Form Digital CMC Consortium to Accelerate Pharmaceutical Development

Rockwell Automation and Industry Leaders Form Digital CMC Consortium to Accelerate Pharmaceutical Development

Rockwell Automation and Industry Leaders Form Digital CMC Consortium to Accelerate Pharmaceutical Development

Galderma Seeks Field Access Manager for Dermatology Market in Great Lakes, St. Louis, Memphis Regions

Galderma Seeks Field Access Manager for Dermatology Market in Great Lakes, St. Louis, Memphis Regions

Galderma Seeks Field Access Manager for Dermatology Market in Great Lakes, St. Louis, Memphis Regions

AI-Enabled Tools Revolutionize Clinical Trial Feasibility, Moving it Upstream in Protocol Development

AI-Enabled Tools Revolutionize Clinical Trial Feasibility, Moving it Upstream in Protocol Development

Artificial Intelligence (AI)-enabled tools are fundamentally changing how clinical trial feasibility is conducted, shifting it from a retrospective validation step to an ongoing, iterative part of protocol development. Traditionally, feasibility studies were performed late in the process, after a protocol was largely finalized, leading to delays and costly amendments if assumptions about cohort sizes, outcome rates, or eligibility criteria proved incorrect. AI tools, such as those offered by TriNetX, now allow study teams to evaluate assumptions against real-world data (RWD) continuously as criteria are being set. This is made possible by natural language interfaces that enable users to enter eligibility criteria in plain language, which the system then translates into clinical code sets to generate patient counts instantly. For example, adjusting a single BMI exclusion criterion in a type 2 diabetes query can change the cohort size by thousands of patients in real-time, providing immediate visual feedback...

Arboretum LifeSciences Secures $30 Million Series A Funding to Advance Genomic Medicine

Arboretum LifeSciences Secures $30 Million Series A Funding to Advance Genomic Medicine

Arboretum LifeSciences Secures $30 Million Series A Funding to Advance Genomic Medicine

Outro Secures $7 Million Funding to Expand Antidepressant Deprescribing Services

Outro Secures $7 Million Funding to Expand Antidepressant Deprescribing Services

Outro, a neuroscience-based platform focused on helping individuals safely discontinue psychiatric medications, has announced $7 million in funding across pre-seed and seed rounds. The funding was secured with participation from investors including Listen Ventures, Cake Ventures, Jason Calicanis’s LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group, and Pave Health Ventures. This capital infusion is intended to accelerate Outro’s mission to address the 'deprescribing gap' in America, starting with antidepressants, and to advance novel research in collaboration with academic institutions. Outro's flagship Taper Management program, co-founded by health tech entrepreneur Brandon Goode and Dr. Mark Horowitz, a leading researcher in deprescribing, is currently available in 14 states. The company aims to build the necessary infrastructure for safe, clinically-supported deprescribing at scale, combining trained clinicians, evidence-informed tapering protocols, patient monitoring, psychosoc...

AstraZeneca Inaugurates New Global Strategic R Center in Kendall Square, Cambridge, Massachusetts

AstraZeneca Inaugurates New Global Strategic R Center in Kendall Square, Cambridge, Massachusetts

AstraZeneca Inaugurates New Global Strategic R Center in Kendall Square, Cambridge, Massachusetts

AI Transforms Clinical Trials with Enhanced Imaging Analysis and Patient Selection

AI Transforms Clinical Trials with Enhanced Imaging Analysis and Patient Selection

Artificial intelligence is revolutionizing clinical trials by significantly improving the speed, standardization, and objectivity of medical imaging analysis. Traditionally, radiologists manually review images like MRI, CT, and PET scans, a process that is time-consuming and prone to variability. AI-driven tools, utilizing deep learning and computer vision, can detect subtle changes in disease progression that are often difficult for humans to quantify. This advancement is leading to faster decision-making in drug development, with industry reports indicating AI can accelerate imaging review timelines by up to 50%. Regulatory agencies are increasingly receptive to AI in clinical trials, provided the tools are properly validated, as AI provides clear, quantifiable evidence crucial for submissions. Beyond imaging, AI is also being used to broaden clinical trial screening and is integrated into adaptive clinical trial designs. The FDA has established the Office of Innovation and Clinical Trial Modernization t...

Servier Acquires Edgewise Therapeutics' Muscular Dystrophy Business to Advance Rare Neurological Disease Treatment

Servier Acquires Edgewise Therapeutics' Muscular Dystrophy Business to Advance Rare Neurological Disease Treatment

Servier, a pharmaceutical company, has completed the acquisition of Edgewise Therapeutics' muscular dystrophy business. This strategic move aims to bolster Servier's research portfolio and expertise in rare neurological diseases, with a specific focus on Becker and Duchenne muscular dystrophies. The acquisition is part of Servier's broader goal to become a global leader in this field by 2030, prioritizing genetic neurological diseases that are severely disabling. Becker muscular dystrophy is a rare, X-linked genetic disorder affecting approximately one in 18,500 live male births, leading to progressive muscle wasting. It impacts an estimated 5,000 to 6,000 male patients in the U.S. and around 35,000 people across the U.S., EU4, Japan, and China. The disease is caused by mutations in the DMD gene, which is responsible for producing dystrophin, a protein crucial for proper muscle function. Currently, there is no approved treatment to slow the progression of Becker muscular dystrophy, and management primarily...

Sensible Biotechnologies Secures $47 Million to Advance Naturally Modified mRNA Platform

Sensible Biotechnologies Secures $47 Million to Advance Naturally Modified mRNA Platform

Sensible Biotechnologies, a company focused on developing naturally modified mRNA medicines, has secured $47 million in financing. This funding includes a Series A round led by Oxford Science Enterprises and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union. The investment will support the advancement and scaling of Sensible's integrated mRNA technology, specifically its VECTOR™ platform. This platform aims to overcome limitations of conventional synthetic mRNA production by using living cells to produce naturally modified mRNA. The company's approach is designed to reduce immunogenicity, achieve high protein expression, and avoid double-stranded RNA (dsRNA) contamination, a common issue with synthetic mRNA. Sensible Biotechnologies plans to use this financing to scale up its VECTOR platform, expand its AI-enabled mRNA design and high-throughput screening capabilities, and develop clinical-grade manufacturing capabilities.

AstraZeneca and Daiichi Sankyo Collaborate on Clinical Trials for Datopotamab Deruxtecan in Cancer Treatment

AstraZeneca and Daiichi Sankyo Collaborate on Clinical Trials for Datopotamab Deruxtecan in Cancer Treatment

AstraZeneca and Daiichi Sankyo Collaborate on Clinical Trials for Datopotamab Deruxtecan in Cancer Treatment

AstraZeneca Invests $2 Billion in Summit Therapeutics for Next-Generation Cancer Drug Combinations

AstraZeneca Invests $2 Billion in Summit Therapeutics for Next-Generation Cancer Drug Combinations

AstraZeneca Invests $2 Billion in Summit Therapeutics for Next-Generation Cancer Drug Combinations